Technical Analysis for NTLA - Intellia Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 14.63 -3.50% -0.53
NTLA closed down 3.5 percent on Friday, January 17, 2020, on approximately normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. It ran into resistance at its 50 day moving average.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical NTLA trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Fell Below 200 DMA Bearish 0.00%
Fell Below 20 DMA Bearish 0.00%
BB Squeeze Ended Range Expansion 0.00%
50 DMA Resistance Bearish -3.50%
Crossed Above 200 DMA Bullish -3.50%
Crossed Above 20 DMA Bullish -3.50%
Bollinger Band Squeeze Range Contraction -3.50%
NR7 Range Contraction -3.50%
BB Squeeze Started Range Contraction -3.50%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. It has a strategic collaboration and license agreement with Novartis focused on the development of new ex vivo CRISPR/Cas9-based therapies. Intellia Therapeutics Inc. was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Medicine Biotechnology Biology Immune System Emerging Technologies Molecular Biology Genetics Inborn Errors Of Metabolism Genome Editing Liver Diseases Antitrypsin Deficiency Chimeric Antigen Receptor Cas9 CRISPR Transthyretin Amyloidosis

Is NTLA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 19.0
52 Week Low 10.26
Average Volume 641,695
200-Day Moving Average 15.12
50-Day Moving Average 15.30
20-Day Moving Average 15.01
10-Day Moving Average 14.76
Average True Range 0.77
ADX 21.47
+DI 21.05
-DI 25.32
Chandelier Exit (Long, 3 ATRs ) 14.75
Chandelier Exit (Short, 3 ATRs ) 15.76
Upper Bollinger Band 16.10
Lower Bollinger Band 13.93
Percent B (%b) 0.32
BandWidth 14.49
MACD Line -0.22
MACD Signal Line -0.18
MACD Histogram -0.032
Fundamentals Value
Market Cap 528.32 Million
Num Shares 36.1 Million
EPS -1.33
Price-to-Earnings (P/E) Ratio -11.00
Price-to-Sales 42.05
Price-to-Book 5.07
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.79
Resistance 3 (R3) 15.91 15.64 15.59
Resistance 2 (R2) 15.64 15.35 15.58 15.53
Resistance 1 (R1) 15.14 15.17 15.01 15.02 15.46
Pivot Point 14.87 14.87 14.81 14.81 14.87
Support 1 (S1) 14.37 14.58 14.24 14.25 13.80
Support 2 (S2) 14.10 14.40 14.04 13.73
Support 3 (S3) 13.60 14.10 13.67
Support 4 (S4) 13.48